Immunoprecise Antibodies Ltd
NASDAQ:HYFT

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
Watchlist
Price: 1.7 USD -1.16% Market Closed
Market Cap: 78.5m USD

Wall Street
Price Targets

HYFT Price Targets Summary
Immunoprecise Antibodies Ltd

Wall Street analysts forecast HYFT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HYFT is 4.08 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.

Lowest
Price Target
3.03 USD
78% Upside
Average
Price Target
4.08 USD
140% Upside
Highest
Price Target
5.25 USD
209% Upside
Immunoprecise Antibodies Ltd Competitors:
Price Targets
SFZN
Siegfried Holding AG
52% Upside
BIO
Bio Rad Laboratories Inc
19% Upside
TECH
Bio-Techne Corp
20% Upside
688222
HitGen Inc
16% Upside
603259
WuXi AppTec Co Ltd
40% Upside
WAT
Waters Corp
8% Upside
QTRX
Quanterix Corp
3% Upside
SLV
Selvita SA
23% Upside

Revenue
Forecast

Revenue Estimate
Immunoprecise Antibodies Ltd

The compound annual growth rate of Immunoprecise Antibodies Ltd's revenue for the next 3 years is 11%.

N/A
Past Growth
11%
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Immunoprecise Antibodies Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Immunoprecise Antibodies Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HYFT's stock price target?
Price Target
4.08 USD

According to Wall Street analysts, the average 1-year price target for HYFT is 4.08 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.

What is Immunoprecise Antibodies Ltd's Revenue forecast?
Projected CAGR
11%

The compound annual growth rate of Immunoprecise Antibodies Ltd's revenue for the next 3 years is 11%.

Back to Top